The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
CUPRIOR (JACE Pharma Pty Ltd)
Product name
CUPRIOR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
212 (255 working days)
Active ingredients
trientine tetrahydrochloride
Registration type
NCE/NBE
Indication
CUPRIOR (film-coated tablet) is indicated for the treatment of Wilson's disease in adults, adolescents and children≥5 years intolerant to D-penicillamine therapy.